Piśmiennictwo

1. Rutkowski P, Wysocki P, Nowecki Z i wsp. Czerniaki skóry — zasady postępowania diagnostyczno-terapeutycznego w 2013 roku. Onkol. Prak. Klin. 2012; 8: 219–233

2. Rutkowski P. (red.). Złośliwe nowotwory skóry. Via Medica Gdańsk 2011; 118−148

3. Dummer R, Hauschild A, Guggenheim M i wsp. on behalf of the ESMO Guidelines Working Group. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (suppl 7): vii86−vii91

4. Stanganelli I, Ascierto P, Bono R i wsp. Impact of mole mapping in the Italian health system. Dermatology 2013; 226 Suppl 1: 13−7

5. The Cancer Council Australia and Australian Cancer Network SaNZGGW. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand, 2008

6. Robertson K, McIntosh RD, Bradley-Scott C i wsp. Image Training, Using Random Images of Melanoma, Performs as Well as the ABC(D) Criteria in Enabling Novices to Distinguish Between Melanoma and Mimics of Melanoma. Acta Derm Venereol 2013; 8 (w druku)

7. McGovern TW, Litaker MS. Clinical predictors of malignant pigmented lesions. A comparison of the Glasgow seven-point checklist and the American Cancer Society’s ABCDs of pigmented lesions. J Dermatol Surg Oncol. 1992;18:22-26

8. Malignant Melanoma S3-Guideline “Diagnosis, Therapy and Follow-up of Melanoma”

9. Braun RP, Oliviero M, Kolm I i wsp. Dermoscopy: what’s new? Clin Dermatol. 2009; 27:26-34

10. Campos-do-Carmo G, Ramos-e-Silva M. Dermatoscopy: basic concepts. Int J Dermatol. 2008; 47:712-719

11. Emery J. Melanoma − Improving diagnosis in general practice. Aust Fam Physician. 2011; 40: 991

12. Chang WY, Huang A, Yang CY i wsp. Computer-aided diagnosis of skin lesions using conventional digital photography: a reliability and feasibility study. 2013;4:e76212

13. Gerger A, Koller S, Kern T i wsp. Diagnostic applicability of in vivo confocal laser scanning microscopy in melanocytic skin tumors. J Invest Dermatol 2005;124:493-8

14. Mali B, Jarm T, Snoj M i wsp. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol. 2013;39:4-16

15. Turley RS, Raymond AK, Tyler DS. Regional treatment strategies for in-transit melanoma metastasis. Surg Oncol Clin N Am. 2011; 20: 79−103

16. Chapman P.B., Hauschild A., Robert C. i wsp. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16

17. Świtaj T, Wysocki P, Wojtukiewicz M i wsp. Ipilimumab – postęp w terapii chorych na zaawansowanego czerniaka. Onkol Prakt Klin 2011;7:231-245

18. Hodi FS, O’Day SJ, McDermott DF i wsp. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723

19. Dostępne na: www.nccn.org

20. Ascierto PA, Kirkwood J, Grob JJ i wsp. The role of BRAF V600 mutation in melanoma. J Transl Med 2012;10:85

21. Sosman JA, Kim KB, Schuchter L i wsp. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Eng J Med 2012;366: 707-714

22. Chapman PB, Hauschild A, Robert C i wsp. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF^V600E-mutated melanoma. J Clin Oncol 2012; 30 (suppl; abstr 8502)

23. Hauschild A, Grob J-J, Demidov LV i wsp. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358−365

24. Ascierto PA, Berking C, Agarwala SS i wsp. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol 2012; 30 (suppl; abstr 8511)

25. Flaherty KT, Robert C, Hersey P i wsp. for the METRIC Study Group. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. N Engl J Med 2012; 367:107-114

26. Dummer R, Rinderknecht J, Goldinger SM i wsp. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol. 2011; 29 (supl.): abstract 8548

27. Rochet NM, Kottschade LA, Markovic SN i wsp. Vemurafenib for Melanoma Metastases to the Brain. N Engl J Med. 2011;365:2439-2441

28. Prieto PA, Yang JC, Sherry RM i wsp. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039-2047

29. Hodi FS, Sznol M, McDermott DF i wsp. Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). J Clin Oncol 2012; 30 (suppl; abstr 8507)